Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2024
Reporting Period: Event-based (July 1, 2024)
This filing reports the entry into a material definitive agreement regarding the Company's "at-the-market" (ATM) equity offering program. The Company updated its registration framework to align with a new universal shelf registration statement (File No. 333-275634) declared effective on December 4, 2023.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, or debt metrics. The filing focuses exclusively on capital market activities.
- ATM Program Aggregate Offering Price: Up to $4,819,905.
- Underwriter: H.C. Wainwright & Co., LLC.
- Trading Symbol: MBOT (NASDAQ Capital Market).
Material Changes
The primary material change is the amendment of the At-the-Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024. Key changes include:
- Re-registration of shares under the 2023 Registration Statement following the expiration of the 2020 Registration Statement.
- Filing of a new prospectus supplement to cover the offering of common stock under the ATM Program.
- Confirmation that sales will be made via transactions deemed "at-the-market offerings" under Rule 415, including sales on the Nasdaq Capital Market or to market makers.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the sale of shares is being made only by means of a prospectus and related prospectus supplement. It explicitly notes that this report does not constitute an offer to sell or a solicitation of an offer to buy shares in jurisdictions where such an offer would be unlawful.
Risks and Contingencies: The filing references the full text of the amendment (Exhibit 10.1) for complete terms. No specific operational risks or contingencies are detailed in the body of this report beyond standard securities law disclaimers.
Investor Verification Checklist
- Verify the current market price of MBOT to assess potential dilution from the $4,819,905 ATM program.
- Review Exhibit 10.1 (Amendment to the At the Market Offering Agreement) for specific terms, commissions, and termination rights.
- Confirm the status of the 2023 Registration Statement (File No. 333-275634) on the SEC EDGAR database.
- Check subsequent filings for actual sales volumes executed under this program.